NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, filed on Tuesday with the SEC to raise up to $40 million in an initial public offering.
The Stans, Switzerland-based company was founded in 2015 and plans to list on the Nasdaq under the symbol NLSP. NLS Pharmaceutics filed confidentially on December 18, 2019. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.
